Skip to main content
. 2015 Sep 10;6(33):34245–34257. doi: 10.18632/oncotarget.5196

Figure 5. JAK2 is activated by CXCL12 and mediates CLL B-lymphocytes static adhesion to ICAM-1 and VCAM-1.

Figure 5

A. Cells were treated with buffer (NT) or CXCL12 0.5 μM for indicated times. Mean ± SD. *P < 0.01; **P < 0.001, versus NT; n = 12 (patients samples) independent experiments in duplicate. B. Cells were treated for 1 h with vehicle (NT and Control), AG490 100 μM, or P1-TKIP 40 μM, and stimulated with CXCL12 0.5 μM for 120 sec. Mean ± SD. *P < 0.01, versus Control; n = 12 (patients samples) independent experiments in duplicate. Static adhesion to ICAM-1 C or VCAM-1 D. Cells were treated for 1 h with vehicle (NT and Control) or with AG490 100 μM, P1 or P1-TKIP 40 μM and stimulated as in (B). Mean ± SD. *P < 0.001, versus Control or P1; data are average of n = 41 independent experiments in triplicate using B-CLL cells isolated from 41 patients.